Endogenic PropDrost Drostanolone Propionate

What is drostanolone propionate?

Drostanolone propionate (chemically 2α-methyl-dihydrotestosterone propionate) is a short-acting ester of drostanolone, a derivative of dihydrotestosterone (DHT). Structurally, the molecule is based on DHT with a methyl group in the 2α position on the A-ring, a modification that blocks breakdown via 3α-hydroxysteroid dehydrogenase in muscle tissue and at the same time makes the molecule completely resistant to aromatization to estrogen. The ester bond in the 17β position in this preparation is propionic acid with three carbons — the shortest ester used in a clinical context.

Drostanolone was developed in the 1950s by Syntex and introduced in the early 1960s under the trade names Drolban, Masteril and Permastril. The propionate ester was the original commercial form and the one used in the oncology clinical trials. The primary indication was the palliative treatment of inoperable breast cancer in postmenopausal women, based on the molecule's antiestrogenic profile. The indication was left when tamoxifen and later aromatase inhibitors showed better tolerability.

The propionate ester, with a tricyclic chain from propionic acid, gives the preparation a half-life of about 2–3 days — significantly shorter than the enant ester. The short half-life gives a quick start to the effect, but also requires frequent administrations to keep the serum level stable. The ratio between anabolic and androgenic activity is stated in the literature to be approximately 62:25 with testosterone as a reference of 100:100.

How does drostanolone propionate work?

After intramuscular injection, an oil depot is formed from which drostanolone propionate slowly diffuses out into the blood. Plasma esterases hydrolyze the ester bond and free drostanolone is released. The shorter ester produces a faster initial peak in serum and a faster decay than long-acting variants, which pharmacokinetically corresponds to a more pulsatile exposure profile.

Free drostanolone binds to the androgen receptor (AR), forms a ligand-receptor complex, and is transported to the cell nucleus, where it controls the transcription of genes linked to protein synthesis and nitrogen balance. The DHT basic structure gives the molecule three distinctive features. The aromatase enzyme cannot act on 5α-reduced steroids, so estrogenic conversion is completely absent. Drostanolone also acts as a weak competitive inhibitor of aromatase — the pharmacological basis for its original oncological use.

The third property concerns the binding to sex hormone-binding globulin (SHBG). Drostanolone has a high affinity for this transport protein and displaces testosterone from SHBG, increasing the fraction of free testosterone in the blood. The DHT structure makes the substance insensitive to 5α-reductase and is not exposed to further activation in the skin or prostate.

What can drostanolone propionate potentially affect?

In the available pharmacological literature and in clinical data from the period when drostanolone was widely used, several physiological systems in which the substance shows an imprint recur:

• Muscle tissue — activation of AR in skeletal muscle cells increases protein synthesis and moderately improves nitrogen balance. The effect is characteristically "dry" because estrogenic water retention is missing.

• Estrogen metabolism — competitive aromatase inhibition and high SHBG affinity alter the ratio of circulating estrogenic and androgenic fractions.

• The hypothalamus-pituitary-gonadal axis (HPG) — like other exogenous androgens, drostanolone via negative feedback lowers the secretion of GnRH as well as LH and FSH, with consequent downregulation of endogenous testosterone production.

• Lipid Metabolism — DHT derivatives shift the lipid profile more markedly than aromatizing compounds, because the liver lacks the counterbalance that estrogen normally exerts on HDL synthesis.

Potential side effects of drostanolone propionate

The side effect profile of drostanolone propionate differs from other anabolic steroids on several points, mainly due to the DHT basic structure of the molecule and the lack of estrogen conversion. However, the absence of estrogenic side effects such as gynecomastia and water retention does not mean that the substance is free of negative effects — on the contrary, several effects become more pronounced due to the unchanged androgenic potential. The short ester's frequent administration requirements also add risk of irritation at the injection site.

• Androgenic effects — acne, seborrhea, oily skin, accelerated male pattern baldness in genetically predisposed individuals, and increased sebum production. These effects tend to be more pronounced than with aromatizing androgens.

• Hormonal changes—suppression of the HPG axis with consequent hypogonadism after cessation of exposure, decreased levels of endogenous testosterone, LH and FSH, and impaired spermatogenesis.

• Cardiovascular effects — unfavorable shift in the lipid profile with lowered HDL and elevated LDL, increased blood pressure and, in the long term, increased risk of left ventricular hypertrophy.

• Hepatological — relatively mild burden because the propionate ester is administered parenterally and bypasses first-pass metabolism, but liver enzyme values may still be shifted with prolonged exposure.

• Psychological — mood swings, irritability, increased aggression and sleep disturbances, and depressed mood in the withdrawal phase.

• In women — pronounced risk of virilization symptoms: voice deepening, hirsutism, clitoral hypertrophy and menstrual disorders. Some changes are permanent even after exposure ends.

• Local — pain, irritation and inflammatory reactions at the injection site are more common with the propionate ester than with long-acting esters, partly because of the frequent administration, partly because of higher osmolarity in the local depot.

The overall side effect picture of drostanolone propionate — marked androgenic character, lipid impact and HPG suppression — means that clinical use requires regular laboratory checks (lipid status, blood count, liver enzymes, hormone panel). The caution applies especially in women, where the virilization effects can be difficult to reverse.